


RealRate

PHARMACEUTICAL 2018

GT Biopharma Inc. Rank 39 of 342







RealRate

GT Biopharma Inc. Rank 39 of 342

The relative strengths and weaknesses of GT Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GT Biopharma Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 1,535% points. The greatest weakness of GT Biopharma Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 70% points.

The company's Economic Capital Ratio, given in the ranking table, is 225%, being 180% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	576
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,679
Liabilities, Non-Current	0
Other Assets	253,786
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-7,677
Other Revenues	0
Property and Equipment	6.0
Research and Development	1,068
Selling, General and Administrative Expense	134,502

Output Variable	Value in 1000 USD
Assets	254,368
Liabilities	2,679
Expenses	135,570
Revenues	0
Stockholders Equity	251,689
Net Income	-143,247
Comprehensive Net Income	-143,247
Economic Capital Ratio	225%

